-
2022-502975-45-00
5
2023-12-12
Metastatic leiomyosarcoma
-
2023-503265-27-00
5
2023-11-23
Participants with Untreated T4N0 or Stage III dMMR/MSI-H Resectable Co
-
2022-502789-26-01
4
2023-11-03
Fibrostenotic Crohn’s Disease
-
2023-503422-39-00
5
2023-10-20
Hepatocellular Carcinoma (HCC)
-
2023-503484-42-00
7
2023-10-19
Advanced, metastatic, solid malignancy
-
2022-500430-29-00
5
2023-10-11
Myelodysplastic Syndrome (MDS)
-
2022-502012-37-00
5
2023-10-06
Advanced Hepatocellular Carcinoma
-
2022-502188-39-00
4
2023-09-27
Dermatitis atopic
-
2022-502695-23-00
1
2023-09-27
Phase 1a Monotherapy Dose Escalation and Exploration: HER2 mutant, HE
-
2022-501346-30-00
5
2023-09-25
Newly Diagnosed Multiple Myeloma with Suboptimal Response After Autolo
-
2023-504028-24-00
5
2023-09-22
Large B-Cell Lymphoma
-
2022-502593-17-00
5
2023-09-19
Locally advanced or metastatic hormone receptor (HR)-positive, human e
-
2022-501419-15-00
5
2023-08-23
Atrial Fibrillation
-
2022-500221-33-01
5
2023-07-28
Hemophilia
-
2024-510627-20-00
5
2023-07-28
Non-alcoholic Steatohepatitis (NASH) Cirrhosis
-
2022-501024-20-00
5
2023-07-25
ER+/HER2- Early Breast Cancer
-
2022-501570-18-00
1
2023-07-18
Recurrent or metastatic Head and NeckSquamous Cell Carcinoma of the or
-
2022-502317-29-00
4
2023-07-12
Advanced Hepatobiliary Cancer
-
2022-501576-25-00
5
2023-07-07
Melanoma
-
2024-515027-11-00
4
2023-06-29
Crohn’s disease
-
2022-502977-41-00
5
2023-06-23
Non-Small Cell Lung Cancer
-
2024-516929-31-00
4
2023-06-19
Patients affected by relapsed/refractory DLBCL or HGBCL failing CAR T-
-
2023-507522-16-00
5
2023-05-22
Metastatic Esophageal or Gastric Cancer
-
2022-500290-14-01
4
2023-05-11
Colitis ulcerative